SAMHD1 and B-cell chronic lymphocytic leukemia: In CLL, mutations were found in 3% pre-treatment and in 11% of refractory/relapsed cases and were associated to lower SAMHD1 protein expression and resistance to agents that induce DNA double strand breaks such as etoposide [24].